PTC Therapeutics

Latest Headlines

Latest Headlines

Scientists dispute PTC's claim on muscular dystrophy drug mechanism

The Scientist is reporting that a group of investigators have completed an in vitro study of their lead treatment and came to a startling conclusion: It doesn't work the way PTC has said it does.

PTC overcomes repeated setbacks to raise $125M in IPO

The market for biotech IPOs has proven strong enough to welcome PTC Therapeutics, a player in the Duchenne muscular dystrophy field with a consistent record of late-stage failure. The biotech announced today that it has priced its IPO at $15, right at the middle of its range, while boosting the number of shares on offer to 8.4 million in order to reap a larger harvest of cash.

UPDATED: PTC, Esperion, bluebird join the IPO frenzy in biotech with genetic therapies

Two more biotech outfits emerged this week as contenders to complete initial public offerings, highlighting the open season for the deals this year. Bluebird bio and PTC Therapeutics has mounted campaigns to go public with pipelines that target the molecular causes of rare genetic diseases.

UPDATED: Biotech PTC reloads coffers with $60M for late-stage DMD drug

PTC Therapeutics has scored new financing to bankroll development of a compound for certain types of Duchenne muscular dystrophy and cystic fibrosis.

PTC investors back lead orphan drug with $30M round

Two years after putting together a $50 million round, PTC Therapeutics has gone back to the venture well and drawn up a bucket of bucks worth $30 million. The money will be used to back the late-stage development of ataluren, PTC's lead program for Duchenne/Becker muscular dystrophy as well as cystic fibrosis.

AVI tanks after positive PhIIb fails to improve outcomes for DMD

AVI Biopharma heralded the news that its lead therapy hit the primary endpoint in a Phase IIb study, increasing levels of dystrophin in a tiny trial for Duchenne muscular dystrophy, but the boys did not experience a significant improvement in walking ability,

Biogen Idec strikes $299M deal for Isis antisense drug

Joining a race of pharma giants to treat rare cases of spinal muscular atrophy, Biogen Idec ($BIIB) has committed up to $299 million to grab rights to an antisense drug program in the pipeline at

Roche, PTC strike potential $490M deal for genetic disease program

Swiss drug giant Roche has bought exclusive rights to PTC Therapeutics ' program for spinal muscular atrophy (SMA) for $30 million upfront, providing PTC with another major pharma collaboration to

Genzyme gives back drug rights to PTC Therapeutics

Genzyme is walking away from a troubled program at PTC Therapeutics after spending $100 million back in 2008 to gain rights in certain markets for ataluren, which is being evaluated to treat rare

AZ financial backing to fuel PTC oncology cures

AstraZeneca and PTC Therapeutics are joining forces for cancer cures, using PTC's proprietary discovery/development technology platform. AZ will front an undisclosed amount of cash to start work on